Partnerships, Licensing, Investments and M and A Deals and Trends for March 2020 in Pharmaceuticals

Summary

The publisher's “Partnerships, Licensing, Investments and M&A Deals and Trends for December 2019 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry.

The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in December 2019.

The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from the publisher's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.
Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
Analysis of partnership and licensing deals based on clinical stage of development of products.
Summary of the pharmaceutical deals globally in the six months.
Information on the top deals happened in the pharmaceutical industry.
Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to Buy

Enhance your decision making capability in a more rapid and time sensitive manner.
Find out the major deal performing segments for investments in your industry.
Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
Identify companies that are aggressively looking to raise capital in the market
Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
Identify growth segments and opportunities in each region within the industry.
Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

1 Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Pharmaceuticals & Healthcare, Global, Deal Summary

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, May 2020
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, May 2020
2.2.1 RegeneronPharma Raises USD6.7 Billion in Public Offering of Shares
2.2.2 Pfizer Prices Public Offering of Notes for USD4 Billion
2.2.3 Amgen Prices Public Offering of Notes for USD4 Billion
2.2.4 Bristol Myers Squibb Enters into Licensing Agreement with Repare Therapeutics
2.2.5 Glaxosmithkline Raises USD2.4 Billion in Public Offering of Bonds
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, May 2020
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, May 2020

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, May 2020

4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, May 2020
4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2020
4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), December 2019- May 2020
4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), December 2019- May 2020
4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), December 2019- May 2020
4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), December 2019- May 2020
4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, May 2020
4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, May 2020
4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, May 2020

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, May 2020
5.1.1 Oncology - Deals of the Month
5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, May 2020
5.2.1 Central Nervous System - Deals of the Month
5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, May 2020
5.3.1 Infectious Diseases - Deals of the Month
5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, May 2020
5.4.1 Cardiovascular - Deals of the Month
5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, May 2020
5.5.1 Immunology - Deal of the Month
5.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, May 2020
5.6.1 Metabolic- Deals of the Month
5.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Disorders, Deals, May 2020
5.7.1 Gastrointestinal - Deals of the Month

6 Deal Summary by Geography

6.1 Pharmaceuticals & Healthcare, North America Deals, May 2020
6.1.1 North America - Deals of the Month
6.2 Pharmaceuticals & Healthcare, Europe, Deals, May 2020
6.2.1 Europe - Deals of the Month
6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, May 2020
6.3.1 Asia-Pacific - Deals of the Month
6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, May 2020
6.4.1 Rest of the World - Deals of the Month

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, December 2019- May 2020
7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, December 2019- May 2020

8 Further Information

8.1 Methodology
8.2 About the Publisher
8.3 Contact
8.4 Disclosure information
8.5 Disclaimer

List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, May 2020
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), May 2020
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, May 2020
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, December 2019- May 2020
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, May 2020
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, May 2020
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, December 2019- May 2020
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), May 2020
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, December 2019- May 2020
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), December 2019- May 2020
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), May 2020
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), December 2019- May 2020
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, December 2019- May 2020
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), December 2019- May 2020
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), December 2019- May 2020
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), May 2020
Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, December 2019- May 2020
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), May 2020
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, May 2020
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, May 2020
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, May 2020
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Table 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Table 38: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), December 2019- May 2020

List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), May 2020
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), May 2020
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, December 2019- May 2020
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, December 2019- May 2020
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), May 2020
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), May 2020
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), December 2019- May 2020
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), December 2019- May 2020
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, December 2019- May 2020
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, December 2019- May 2020
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), December 2019- May 2020
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), December 2019- May 2020
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), December 2019- May 2020
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, December 2019- May 2020
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), December 2019- May 2020
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), May 2020
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Figure 32: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Figure 33: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), December 2019- May 2020
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), December 2019- May 2020

Table of Contents

Related Topics

Related Reports

Pharmaceutical Drugs Global Market Report 2023

Pharmaceuticals Industry Deals and Trends in November 2022 - Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)

Royalty Rates in Pharmaceuticals and Biotechnology Deals

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016 - 2023

Drafting Commercial Contracts for the Pharmaceutical Industry Training Course (November 22-23, 2023)